Skip to main content

The Mechanism of Action of CDK4/6 Inhibitors

Breast Cancer, SABCS 2017 Highlights, SABCS Highlights
Videos

Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.

Related Items

Radiation May be Safely Omitted in Favorable-Risk Breast Cancer Patients Aged 50 to 69 Years
By Phoebe Starr
February 2024, Vol 14, No 2
SABCS Highlights
Fertility Preservation Does Not Increase Risk of Recurrence of HR–Positive Breast Cancer
By Wayne Kuznar
January 2024, Vol 14, No 1
SABCS Highlights
Adjuvant T-DM1 Improves Survival vs Trastuzumab in Early High-Risk HER2-Positive Breast Cancer
By Phoebe Starr
January 2024, Vol 14, No 1
SABCS Highlights
HER2-Directed Combination Improves Outcomes in Advanced HER2-Positive Breast Cancer, Including Patients With Brain Metastases
By Wayne Kuznar
January 2024, Vol 14, No 1
SABCS Highlights